1. Surgical ovarian suppression for adjuvant treatment in hormone receptor positive breast cancer in premenopausal patients.
- Author
-
Oseledchyk A, Gemignani ML, Zhou QC, Iasonos A, Elahjji R, Adamou Z, Feit N, Goldfarb SB, Long Roche K, Sonoda Y, Goldfrank DJ, Chi DS, Saban SS, Broach V, Abu-Rustum NR, Carter J, Leitao M, and Zivanovic O
- Subjects
- Adult, Breast Neoplasms pathology, Chemotherapy, Adjuvant, Databases, Factual, Female, Gonadotropin-Releasing Hormone administration & dosage, Humans, Middle Aged, Retrospective Studies, Salpingo-oophorectomy methods, Salpingo-oophorectomy statistics & numerical data, Breast Neoplasms surgery, Premenopause, Salpingo-oophorectomy adverse effects
- Abstract
Objective: Ovarian suppression is recommended to complement endocrine therapy in premenopausal women with breast cancer and high-risk features. It can be achieved by either medical ovarian suppression or therapeutic bilateral salpingo-oophorectomy. Our objective was to evaluate characteristics of patients with stage I-III hormone receptor positive primary breast cancer who underwent bilateral salpingo-oophorectomy at our institution., Materials and Methods: Premenopausal women with stage I-III hormone receptor positive primary breast cancer diagnosed between January 2010 and December 2014 were identified from a database. Patients with confirmed BRCA1/2 mutations were excluded. Distribution of characteristics between treatment groups was assessed using χ
2 test and univariate logistic regression. A multivariate model was based on factors significant on univariate analysis., Results: Of 2740 women identified, 2018 (74%) received endocrine treatment without ovarian ablation, 516 (19%) received endocrine treatment plus ovarian ablation, and 206 (7.5%) did not receive endocrine treatment. Among patients undergoing ovarian ablation 282/516 (55%) received medical ovarian suppression, while 234 (45%) underwent bilateral salpingo-oophorectomy. By univariate logistic analyses, predictors for ovarian ablation were younger age (OR 0.97), histology (other vs ductal: OR 0.23), lymph node involvement (OR 1.89), higher International Federation of Gynecology and Obstetrics (FIGO) stage (stage II vs I: OR 1.48; stage III vs I: OR 2.86), higher grade (grade 3 vs 1: OR 3.41; grade 2 vs 1: OR 2.99), chemotherapy (OR 1.52), and more recent year of diagnosis (2014 vs 2010; OR 1.713). Only year of diagnosis, stage, and human epidermal growth factor receptor 2 (HER-2) treatment remained significant in the multivariate model. Within the cohort undergoing ovarian ablation, older age (OR 1.05) was associated with therapeutic bilateral salpingo-oophorectomy. Of 234 undergoing bilateral salpingo-oophorectomy, 12 (5%) mild to moderate adverse surgical events were recorded., Conclusions: Bilateral salpingo-oophorectomy is used frequently as an endocrine ablation strategy. Older age was associated with bilateral salpingo-oophorectomy. Perioperative morbidity was acceptable. Evaluation of long-term effects and quality of life associated with endocrine ablation will help guide patient/provider decision-making., Competing Interests: Competing interests: None declared., (© IGCS and ESGO 2021. No commercial re-use. See rights and permissions. Published by BMJ.)- Published
- 2021
- Full Text
- View/download PDF